Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics.
about
The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.Organizational implementation of evidence-based substance abuse treatment in racial and ethnic minority communitiesRepresentation of women and pregnant women in HIV research: a limited systematic review.Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centersChallenges in managing HIV in people who use drugsHIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.Impact of Illicit Drug Use on Health-Related Quality of Life in Opioid-Dependent Patients Undergoing HIV Treatment.Correlates of antiretroviral utilization among hospitalized HIV-infected crack cocaine users.Short term health-related quality of life improvement during opioid agonist treatmentAssociation between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment.Exploring How Substance Use Impedes Engagement along the HIV Care Continuum: A Qualitative Study"Bureaucracy & Beliefs": Assessing the Barriers to Accessing Opioid Substitution Therapy by People Who Inject Drugs in Ukraine.HIV infection among people who inject drugs: the challenge of racial/ethnic disparities.The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment.Factors associated with physical and sexual violence by police among people who inject drugs in Ukraine: implications for retention on opioid agonist therapyIntegration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine.Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review.Days of heroin use predict poor self-reported health in hospitalized heroin users.Health-Related Quality of Life in HIV-Infected and At-Risk Women: The Impact of Illicit Drug Use and Hepatitis C on a Community Preference Weighted Measure.Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies.A mixed methods study of HIV-related services in buprenorphine treatment.Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review.Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.Primary care models for treating opioid use disorders: What actually works? A systematic reviewCharacterizing Long-Term Health Related Quality of Life Trajectories of Individuals With Opioid Use DisorderThe effects of Buprenorphine/Naloxane Maintenance Treatment on the Quality of Life, Substance Use and Functionality in Opiate Dependence: A Follow-Up Study
P2860
Q33644060-88BDD34F-1C4E-4165-82B9-A7F5BCFE2D1BQ33707278-F89416D5-9C95-463C-838A-3847433CA970Q34979789-03D37D32-0E67-4E58-92AA-4207B44934FCQ35112836-25A56977-1DCC-4287-9424-498E9D78DDD6Q35538674-D2478F6D-27C0-4045-87FE-E8C7A8188FB9Q35686969-171E9A7B-BDFA-4FD4-83BB-B0DAB023DDBAQ36167178-F1AE543E-2C4B-4315-B272-7BE2EB5EEAC5Q36177517-F03243F5-5AD7-4F89-96DF-D0A43A683ECEQ36652120-B2970D64-D986-4AA7-9316-964964ACB09DQ36745453-04369637-3864-4FE8-A925-1420C17F4F29Q36777836-6DFEEA95-6C24-460F-8557-E6945296AF1BQ36798287-4168A68D-13CC-428D-B872-ADC51EA725C8Q37009231-D2FB78D0-531C-49A5-9CBC-7E91DAA82B92Q37035765-BE4C1099-FD7B-4FC2-AC0D-19A5DEF3C8A4Q37110382-7361CCF5-BD50-46D8-8F9D-ACDD03DBED39Q37397043-891C9A85-1249-4821-8588-EC4692C309C9Q37433660-8593A2DC-F28E-40E0-983D-59AE21F09904Q37438987-953639FA-1EEE-4B4A-8CAC-CFD9BAE46FA5Q37693067-5AB55E88-22C8-413D-9B2F-06337BC8AC99Q38244651-7841A678-0170-4F33-9AB7-B1F606D2CE4BQ38621655-4838A479-F946-4B32-9DB2-E2C025C87F89Q39029605-FA76FD1E-07A0-4400-A9A8-CDA9CB495A1DQ40382481-5EA81244-337F-4AD3-BA99-ACF2F1C9DD47Q42656779-1928998F-13DA-40C4-80A0-4AB1425E999DQ42709317-9E1065AC-12DB-46FD-B0EA-52BCA659A45BQ58826486-C2AEDF5F-36D0-48B0-BB93-4601321213B9
P2860
Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Improved quality of life for o ...... hine treatment in HIV clinics.
@ast
Improved quality of life for o ...... hine treatment in HIV clinics.
@en
Improved quality of life for o ...... hine treatment in HIV clinics.
@nl
type
label
Improved quality of life for o ...... hine treatment in HIV clinics.
@ast
Improved quality of life for o ...... hine treatment in HIV clinics.
@en
Improved quality of life for o ...... hine treatment in HIV clinics.
@nl
prefLabel
Improved quality of life for o ...... hine treatment in HIV clinics.
@ast
Improved quality of life for o ...... hine treatment in HIV clinics.
@en
Improved quality of life for o ...... hine treatment in HIV clinics.
@nl
P2093
P2860
P50
P1476
Improved quality of life for o ...... hine treatment in HIV clinics.
@en
P2093
Angela Acosta
BHIVES Collaborative
David Hersh
Frederick L Altice
Jeffrey Hsu
Joshua Boverman
Linda Weiss
Mary Jo Tozzi
Michael Botsko
P Todd Korthuis
P2860
P304
P356
10.1097/QAI.0B013E318209754C
P407
P478
56 Suppl 1
P577
2011-03-01T00:00:00Z